Latest News
-

Huntington's Disease Therapeutics Conference 2016 – day 1
⏱️ 12 min read
Proteins and DNA – Jeff and Ed report from day 1 of the 2016 #huntingtonsdisease therapeutics conference
-

Harnessing the power of viruses to treat Huntington's disease
⏱️ 7 min read
Researchers design a virus to more effectively deliver gene-silencing drugs throughout the brain.
-

Through a Broader Lens: Looking at Non-Motor Symptoms in HD
⏱️ 8 min read
Sleep deficits precede motor problems in HD
-

Looking Past the Spin: Results from a Clinical Trial of Cysteamine
⏱️ 6 min read
Phase 2/3 clinical trial results prove inconclusive for Huntington's drug cysteamine.
-

A recycled drug gives us new insight in to HD
⏱️ 7 min read
An existing drug could give a boost to HD brain cells – but it may need more testing before it’s back in the clinic
-

Through the eyes of a friend: changes in mood and behavior in early HD
⏱️ 8 min read
Companions of HD gene carriers are more likely to notice psychological changes in presymptomatic HD.
-

A multiple sclerosis drug that works for Huntington's disease: the real deal or too good to be true?
⏱️ 8 min read
Fingolimod, a drug used in multiple sclerosis, prevents memory problems in HD mice. Would it work in patients?
-

Mapping the anatomy of HD: a whole-brain history
⏱️ 10 min read
A new book for researchers describes a century of HD anatomy and presents evidence that HD affects the whole brain.
-

Liftoff: First humans treated with gene silencing drugs for HD!
⏱️ 8 min read
Major Announcement: First HD patients treated with gene silencing drugs
-

HDBuzz primer: Clinical trial designs and phases
⏱️ 17 min read
HDBuzz untangles hope from hype in clinical trial announcements
HDBuzz Trial Tracker
FDA accepts BLA for Priority Review, with a target decision date of 1 May 2027.
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
Previously featured
-
EHDN 2026 Part 2: What’s the latest news for Huntington’s disease clinical trials?
-
EHDN 2026 Part 1: What’s next in the Huntington’s disease treatment pipeline?
-
Skyhawk’s drug trial takes flight in the US
-
FDA sets May 2027 decision date on AMT-130 gene therapy for HD
-
October 2026: This Month in Huntington’s Disease Research
Follow HDBuzz
Sign up to our monthly email summary by entering your email address on our mailing list page.
Suggest an article
Is there something you want us to write about? Tell us about it here. We consider all suggestions but can’t promise to write content about any particular suggestion.
